Immune checkpoints inhibitors in cancer therapy-current status and future prospects
Keywords:
checkpoint receptor, immune checkpoint inhibitors, checkpoint ligands, CTLA-4, PD-1, immunotherapy, cancer treatmentAbstract
The field of oncology is revolutionized by immunotherapy. immunotherapy is a fundamental breakthrough in cancer treatment that focuses on boosting the natural defense for malignant cell elimination. Cancer immunotherapy is of different forms including, virus therapies, adoptive cell transfer, cytokine therapies, immune checkpoint inhibitors, and cancer vaccines, all of which have promise future developments and clinical applications. To maintain homeostasis several pathways of immune signaling are employed that inhibit or stimulate immune responses. These immune signaling pathways help to keep immune responses maintained by avoiding autoimmunity and chronic inflammation, these immune signals that regulate immune responses in the body are also known as immune checkpoints. The responses of numerous self-regulating checkpoints of the immune system are exploited by the cancerous cells. Immune checkpoint inhibitors and monoclonal antibodies (mAbs) are becoming the most important immunotherapies, despite the progress of Acceptance and Commitment Therapy (ACT). ICIs are the antibodies that inhibit the receptors of the immune checkpoint, PD-1/PD-L1, and CTLA-4. It has potential benefits in cancer treatment for long-term survival and antitumor effect production in malignancies of a broad spectrum.
Downloads
References
Akinleye, A., & Rasool, Z. (2019). Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of hematology & oncology, 12(1), 1-13.
Alegre, M. L., Frauwirth, K. A., & Thompson, C. B. (2001). T-cell regulation by CD28 and CTLA-4. Nature Reviews Immunology, 1(3), 220-228.
Ayoub, N. M., Al-Shami, K. M., & Yaghan, R. J. (2019). Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer: Targets and Therapy, 11, 53.
Bashiri Dezfouli, A., Yazdi, M., Pockley, A. G., Khosravi, M., Kobold, S., Wagner, E., & Multhoff, G. (2021). NK cells armed with chimeric antigen receptors (CAR): Roadblocks to successful development. Cells, 10(12), 3390.
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: current advances and future directions. International journal of medical sciences, 9(3), 193.
Bianco, P., Riminucci, M., Gronthos, S., & Robey, P. G. (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. Stem cells, 19(3), 180-192.
Bucht, A., Larsson, P., Weisbrot, L., Thorne, C., Pisa, P., Smedegård, G., ... & Grönberg, A. (1996). Expression of interferon‐gamma (IFN‐δ), IL‐10, IL‐12 and transforming growth factor‐beta (TGF‐β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clinical & Experimental Immunology, 103(3), 357-367.
Chambers, C. A., & Allison, J. P. (1997). Co-stimulation in T cell responses. Current opinion in immunology, 9(3), 396-404.
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019). Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 30(1), 44-56.
Chang, L., Chang, M., Chang, H. M., & Chang, F. (2018). Microsatellite instability: a predictive biomarker for cancer immunotherapy. Applied Immunohistochemistry & Molecular Morphology, 26(2), e15-e21.
Chauvin, J. M., & Zarour, H. M. (2020). TIGIT in cancer immunotherapy. Journal for immunotherapy of cancer, 8(2).
Chouthai, A., Makar, M., & Sarkar, A. (2021). Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). In Hepato-Pancreato-Biliary Malignancies: Diagnosis and Treatment in the 21st Century (pp. 1-27). Cham: Springer International Publishing.
Croft, M. (2009). The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology, 9(4), 271-285.
de Coaña, Y. P., Choudhury, A., & Kiessling, R. (2015). Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in molecular medicine, 21(8), 482-491.
De Silva, D. D., Rapior, S., Fons, F., Bahkali, A. H., & Hyde, K. D. (2012). Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action. Fungal Diversity, 55(1), 1-35.
DeVita Jr, V. T., & Chu, E. (2008). A history of cancer chemotherapy. Cancer research, 68(21), 8643-8653.
Fife, B. T., & Bluestone, J. A. (2008). Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways. Immunological reviews, 224(1), 166-182.
Friedrich, T., Henthorn, N., & Durante, M. (2021). Modeling radioimmune response—current status and perspectives. Frontiers in Oncology, 11, 647272.
Haley, B., & Frenkel, E. (2008, January). Nanoparticles for drug delivery in cancer treatment. In Urologic Oncology: Seminars and original investigations (Vol. 26, No. 1, pp. 57-64). Elsevier.
He, J., Hu, Y., Hu, M., & Li, B. (2015). Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Scientific reports, 5(1), 1-9.
Hellman, S., & Vokes, E. E. (1996). Advancing current treatments for cancer. Scientific American, 275(3), 118-123.
Izcue, A., Coombes, J. L., & Powrie, F. (2006). Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunological reviews, 212(1), 256-271.
Jamuna, R. (2015). Data mining technique applied to DNA sequencing. International Research Journal of Management, IT and Social Sciences, 2(7), 15-19. Retrieved from https://sloap.org/journals/index.php/irjmis/article/view/314
Kang, S. H., Hwang, H. J., Yoo, J. W., Kim, H., Choi, E. S., Hwang, S. H., ... & Koh, K. N. (2019). Expression of immune checkpoint receptors on T-cells and their ligands on leukemia blasts in childhood acute leukemia. Anticancer Research, 39(10), 5531-5539.
Kisielow, M., Kisielow, J., Capoferri‐Sollami, G., & Karjalainen, K. (2005). Expression of lymphocyte activation gene 3 (LAG‐3) on B cells is induced by T cells. European journal of immunology, 35(7), 2081-2088.
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., ... & von Bergwelt-Baildon, M. (2019). Advances in cancer immunotherapy 2019–latest trends. Journal of Experimental & Clinical Cancer Research, 38(1), 1-11.
Lee, L., Gupta, M., & Sahasranaman, S. (2016). Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy. The journal of clinical pharmacology, 56(2), 157-169.
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clinical therapeutics, 37(4), 764-782.
Mardis, E. R. (2019). Neoantigens and genome instability: Impact on immunogenomic phenotypes and immunotherapy response. Genome medicine, 11(1), 1-12.
Markiewicz, D. A., Schultz, D. J., Haas, J. A., Harris, E. E., Fox, K. R., Glick, J. H., & Solin, L. J. (1996). The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. International Journal of Radiation Oncology* Biology* Physics, 35(4), 661-668.
Maruyama, K., Okabayashi, K., & Kinoshita, T. (1987). Progress in gastric cancer surgery in Japan and its limits of radicality. World journal of surgery, 11(4), 418-425.
Mba, I. E., & Nweze, E. I. (2022). Application of Nanotechnology in the Treatment of Infectious Diseases: An Overview. Nanotechnology for Infectious Diseases, 25-51.
Murphy, J. T. (2015). Anaphylaxis caused by repetitive doses of a GITR agonist antibody. Weill Medical College of Cornell University.
Old, L. J. (1996). Immunotherapy for cancer. Scientific American, 275(3), 136-143.
Pandey, P., Khan, F., Qari, H. A., Upadhyay, T. K., Alkhateeb, A. F., & Oves, M. (2022). Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals, 15(3), 335.
Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P. (2016). Harnessing the immune system to improve cancer therapy. Annals of translational medicine, 4(14).
Pauken, K. E., & Wherry, E. J. (2015). Overcoming T cell exhaustion in infection and cancer. Trends in immunology, 36(4), 265-276.
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009). Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clinical & Experimental Immunology, 157(1), 9-19.
Porter, L. S., Keefe, F. J., Garst, J., Baucom, D. H., McBride, C. M., McKee, D. C., ... & Scipio, C. (2011). Caregiver-assisted coping skills training for lung cancer: results of a randomized clinical trial. Journal of pain and symptom management, 41(1), 1-13.
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019). Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Molecular cancer, 18(1), 1-14.
Ramsay, A. G. (2013). Immune checkpoint blockade immunotherapy to activate anti‐tumour T‐cell immunity. British journal of haematology, 162(3), 313-325.
Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C., & Kuchroo, V. K. (2011). Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in immunology, 32(8), 345-349.
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019). PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy. Journal of cellular physiology, 234(10), 16824-16837.
Sarfati, D., Koczwara, B., & Jackson, C. (2016). The impact of comorbidity on cancer and its treatment. CA: a cancer journal for clinicians, 66(4), 337-350.
Shamseddine, A. A., Burman, B., Lee, N. Y., Zamarin, D., & Riaz, N. (2021). Tumor Immunity and Immunotherapy for HPV-Related CancersTumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer discovery, 11(8), 1896-1912.
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., ... & Chan, T. A. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England Journal of Medicine, 371(23), 2189-2199.
Suryatika, I. B. M., Anggarani, N. K. N., Poniman, S., & Sutapa, G. N. (2020). Potential risk of cancer in body organs as result of torak CT-scan exposure. International Journal of Physical Sciences and Engineering, 4(3), 1–6. https://doi.org/10.29332/ijpse.v4n3.465
Ventafridda, V., Tamburini, M., Caraceni, A., De Conno, F., & Naldi, F. (1987). A validation study of the WHO method for cancer pain relief. Cancer, 59(4), 850-856.
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017). Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics, 37(7), 2132-2144.
Weber, J. (2010, October). Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. In Seminars in oncology (Vol. 37, No. 5, pp. 430-439). WB Saunders.
Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Vendetti, F., ... & Baylin, S. B. (2013). Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget, 4(11), 2067.
Zhang, Y., & Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & molecular immunology, 17(8), 807-821.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
